Drug intelligence / Profile preview

CM-942

Development stage: Unknown
Lead developer: Carmot Therapeutics

Overview

CM-942 is a drug candidate developed by Carmot Therapeutics. It was undergoing Phase 2 clinical trials for obesity indications. Roche acquired Carmot Therapeutics, including CM-942, with the aim of expanding its pipeline in obesity and metabolic diseases and leveraging Carmot’s novel chemistry platform.

Beyond the preview

Go deeper on CM-942.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CM-942.

Explore the full profile